- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- May 2024
- 134 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2021
- 50 Pages
China
From €2481EUR$2,600USD£2,079GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2025
- 82 Pages
Saudi Arabia
From €3340EUR$3,500USD£2,799GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- June 2019
- 18 Pages
Global
€9544EUR$10,000USD£7,996GBP
- Report
- May 2022
- 71 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- February 2024
- 114 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- November 2021
- 620 Pages
Global
From €3818EUR$4,000USD£3,199GBP
Dolutegravir is a medication used to treat immune disorders, such as HIV and AIDS. It is a type of integrase inhibitor, which works by blocking the action of the enzyme integrase, which is responsible for the integration of HIV genetic material into the host cell. Dolutegravir is used in combination with other antiretroviral drugs to treat HIV infection. It is also used to prevent HIV infection in people who are at high risk of contracting the virus. Dolutegravir is generally well tolerated and has few side effects.
Dolutegravir is a relatively new drug, and its use in the treatment of immune disorders is still being studied. It is currently approved for use in the United States, Europe, and other countries. The drug is available in both generic and branded forms.
Companies in the dolutegravir market include ViiV Healthcare, Gilead Sciences, Merck, and Bristol-Myers Squibb. Show Less Read more
